Research Topics
Species | CHARLES PATRICK REYNOLDSSummaryAffiliation: University of Southern California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Retinoid therapy of high-risk neuroblastomaC Patrick Reynolds
Division of Hematology Oncology, Children s Hospital of Los Angeles and the University of Southern California Keck School of Medicine, Los Angeles, CA 90054, USA
Cancer Lett 197:185-92. 2003..Thus, further clinical trials of 4-HPR in neuroblastoma, and of 4-HPR in combination with ceramide modulators, are warranted...- Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinideC P Reynolds
Division of Hematology Oncology, Childrens Hospital Los Angeles, Los Angeles, California 90027, USA
Med Pediatr Oncol 35:597-602. 2000..High-dose, pulse-13-cis-retinoic acid (13-cis-RA) given after intensive cytotoxic therapy improves event-free survival for high-risk neuroblastoma (NB), but more than 50% of patients have tumor recurrence... - Assessing combinations of cytotoxic agents using leukemia cell linesC Patrick Reynolds
Developmental Therapeutics Program, Institute for Pediatric Clinical Research, Department of Pediatrics, Keck School of Medicine, University of Southern California and Childrens Hospital Los Angeles, CA 90027, USA
Curr Drug Targets 8:765-71. 2007..to be the most suitable for evaluating of drug interactions in cell culture assays... - Detection and treatment of minimal residual disease in high-risk neuroblastomaC Patrick Reynolds
Developmental Therapeutics Program, USC CHLA Institute for Pediatric Clinical Research, Childrens Hospital Los Angeles, CA 90027, USA
Pediatr Transplant 8:56-66. 2004..18-IL2 immunocytokine. It is anticipated that testing novel approaches to treating neuroblastoma MRD will be the subject of future phase-III randomized trials... - Ceramide synthesis and metabolism as a target for cancer therapyC Patrick Reynolds
Division of Hematology Oncology MS 57, Children s Hospital of Los Angeles, The University of Southern California Keck School of Medicine, 4650 Sunset Blvd, Los Angeles, CA 90054 0700, USA
Cancer Lett 206:169-80. 2004..Thus, pharmacological manipulation of sphingolipid metabolism to enhance tumor cell ceramide is being realized and offers a novel approach to cancer chemotherapy... - Differentiating agents in pediatric malignancies: retinoids in neuroblastomaC P Reynolds
Division of Hematology Oncology, Children s Hospital of Los Angeles and The University of Southern California School of Medicine, 4650 Sunset Boulevard Los Angeles, CA 90054 0700, USA
Curr Oncol Rep 2:511-8. 2000.... - Retinoid therapy of childhood cancerC P Reynolds
Developmental Therapeutics Section, Division of Hematology Oncology, Children s Hospital of Los Angeles, University of Southern California, Keck School of Medicine, Los Angeles, California, USA
Hematol Oncol Clin North Am 15:867-910. 2001..Clinical trials of fenretinide, alone and in combination with ceramide modulators, are in development... - Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulatorsSandeep Batra
Division of Hematology-Oncology, Children's Hospital Los Angeles, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA
Cancer Res 64:5415-24. 2004.... - A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinationsTomas Frgala
Developmental Therapeutics Program, USC CHLA Institute for Pediatric Clinical Research, Children s Hospital Los Angeles, MS 57, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA
Mol Cancer Ther 6:886-97. 2007..Using DIMSCAN, a fluorescence digital image system for quantifying relative cell numbers in tissue culture plates, we have developed a 96-well cytotoxicity assay with a >4-log dynamic range... - Tirapazamine cytotoxicity for neuroblastoma is p53 dependentBo Yang
Developmental Therapeutics Program, USC-CHLA Institute for Pediatric Clinical Research, Division of Hematology-Oncology, Children's Hospital Los Angeles, California
Clin Cancer Res 11:2774-80. 2005..These data further define the mechanism of action of TPZ and suggest that as a single agent, TPZ would only have clinical activity against p53-functional neuroblastomas... - Flow cytometry analysis of single-strand DNA damage in neuroblastoma cell lines using the F7-26 monoclonal antibodyRita S Grigoryan
Developmental Therapeutics Program, USC CHLA Institute for Pediatric Clinical Research, Los Angeles, California 90027, USA
Cytometry A 71:951-60. 2007..These data demonstrate that Mab F7-26 recognized ssDNA due to exogenous DNA damage, rather than apoptosis. This assay should be useful to characterize the mechanism of action of antineoplastic drugs... - Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53Nino Keshelava
Department of Pediatrics, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
Clin Cancer Res 9:3492-502. 2003..Prolonged systemic exposure to PZA with hematopoietic stem cell support may be effective against recurrent neuroblastomas that have failed conventional chemotherapeutic regimens, including those neuroblastomas with loss of p53 function... - Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamineBo Yang
Division of Hematology-Oncology, Children's Hospital Los Angeles, California 90027, USA
Cancer Res 63:1520-6. 2003..These data additionally define the role of ROS in BSO-mediated cytotoxicity and suggest that combining BSO with TPZ could have clinical activity against NB in hypoxic sites... - The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferationHongjun Peng
Division of Hematology Oncology, Department of Pediatrics, University of Southern California, USA
Cancer Res 67:9346-55. 2007.... - DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapyNino Keshelava
USC-CHLA Institute for Pediatric Clinical Research, University of Southern California and Childrens Hospital Los Angeles, Los Angeles, CA, USA
Methods Mol Med 110:139-53. 2005..DIMSCAN has been used to demonstrate preclinical activity of cytotostatic and cytotoxic drugs and drug combinations that have subsequently shown activity in clinical trials... - Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell linesHiroaki Goto
Divisions of Hematology-Oncology and Research Immunology/Bone Marrow Transplantation, Childrens Hospital Los Angeles, CA 90027, USA
Mol Cancer Ther 2:911-7. 2003..Our data suggest caution when employing GFP-transduced cells to assess drug sensitivity and that using a cell surface antigen as a selection marker for gene transduction may perturb cells less than GFP... - Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptideNino Keshelava
Institute for Pediatric Clinical Research and Division of Hematology Oncology, Childrens Hospital Los Angeles, University of South California, Los Angeles, CA 90027, USA
J Natl Cancer Inst 99:1107-19. 2007..Genes that are overexpressed in multidrug-resistant neuroblastomas relative to drug-sensitive neuroblastomas may provide targets for modulating drug resistance... 
Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivationMin H Kang
Division of Hematology Oncology, USC CHLA Institute for Pediatric Clinical Research, Children s Hospital Los Angeles, Los Angeles, CA 90027, USA
J Natl Cancer Inst 100:580-95. 2008..Thus, we investigated whether 4-HPR-mediated inactivation of Mcl-1 could act synergistically with ABT-737 to promote leukemia cell death...- Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivoMin H Kang
Developmental Therapeutics Program, Childrens Hospital Los Angeles and University of Southern California Institute for Pediatric Clinical Research, Los Angeles, CA 90027, USA
Blood 110:2057-66. 2007..Combining VXL with a BH3-mimetic warrants clinical investigation in ALL at relapse and potentially in chemotherapy-resistant ALL subgroups... - Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complexBarry J Maurer
Developmental Therapeutics Program, USC CHLA Institute for Pediatric Clinical Research and Division of Hematology Oncology, Childrens Hospital Los Angeles, Los Angeles, CA 90027, USA
Clin Cancer Res 13:3079-86. 2007..To support the hypothesis that a novel organized lipid matrix, LYM-X-SORB, can increase the oral bioavailability of fenretinide, fenretinide in LYM-X-SORB matrix and in a powderized LYM-X-SORB formulation was delivered to mice... 
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing programNino Keshelava
Children s Hospital of Los Angeles, Los Angeles, California 90027, USA
Pediatr Blood Cancer 53:505-8. 2009..Preclinical studies with appropriate drug combinations may provide direction for further clinical evaluations of vorinostat against selected pediatric cancers...- Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709)Judith G Villablanca
Children s Hospital Los Angeles and the Department Pediatrics, University of Southern California Keck School of Medicine, Los Angeles, USA
J Clin Oncol 24:3423-30. 2006..To determine the maximal tolerated dosage (MTD) of oral fenretinide given as intact capsules for 7 days, repeated every 21 days, in children with high-risk solid tumors... - Ceramide signaling in fenretinide-induced endothelial cell apoptosisAnat Erdreich-Epstein
Division of Hematology Oncology, Department of Pediatrics, Childrens Hospital Los Angeles, Keck School of Medicine, University of Southern California, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA
J Biol Chem 277:49531-7. 2002..Our results provide the first evidence that increased ceramide biosynthesis is required for 4-HPR-induced endothelial apoptosis and present a molecular mechanism for its antiangiogenic effects... - Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium StudyKatherine K Matthay
Department of Pediatrics, University of California, San Francisco, School of Medicine, and UCSF Children s Hospital, San Francisco, CA 94143 0106, USA
J Clin Oncol 24:500-6. 2006..To determine the maximum-tolerated dose (MTD) and toxicity of iodine-131-metaiodobenzylguanidine ((131)I-MIBG) with carboplatin, etoposide, melphalan (CEM) and autologous stem-cell transplantation (ASCT) in refractory neuroblastoma... - Assessing growth and response to therapy in murine tumor modelsC Patrick Reynolds
USC-CHLA Institute of Pediatric Clinical Research, University of Southern California and Childrens Hospital Los Angeles, USA
Methods Mol Med 111:335-50. 2005.... - Evaluating response to antineoplastic drug combinations in tissue culture modelsC Patrick Reynolds
USC-CHLA Institute for Pediatric Clinical Research, University of Southern California and Childrens Hospital Los Angeles, Los Angeles, CA, USA
Methods Mol Med 110:173-83. 2005..We focus this review on application of the Combination Index method (as developed by Chou and colleagues) in the evaluation of drug interactions in cell culture assays... - Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activityTheresa M Harned
Developmental Therapeutics Program, USC CHLA Institute for Pediatric Clinical Research, Keck School of Medicine, University of Southern California and Children s Hospital Los Angeles, Los Angeles, CA 90027, USA
Clin Cancer Res 14:533-40. 2008.... - Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonateYasuyoshi Sohara
Department of Pediatrics, Division of Hematology-Oncology, Childrens Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, California 90027, USA
Cancer Res 63:3026-31. 2003..The data suggest that bisphosphonates may be clinically effective in the treatment of bone metastases in neuroblastoma... - GABAergic system gene expression predicts clinical outcome in patients with neuroblastomaStephen S Roberts
Department of Pediatrics, NRC-5, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
J Clin Oncol 22:4127-34. 2004..CONCLUSION: Dysregulation of the GABAergic system may constitute a fundamental event in the development of NB, and assessment of GABAergic system gene expression could provide improved patient stratification and potential new therapies... - In vitro testing of chemosensitivity in physiological hypoxiaRita Grigoryan
Developmental Therapeutics Section, Children's Hospital of Los Angeles, Los Angeles, CA, USA
Methods Mol Med 110:87-100. 2005..We review the impact of hypoxia on anticancer drug cytotoxicity and the methods used in our laboratory to asses the cytotoxic activity of single antineoplastic drugs under conditions of physiological hypoxia... - Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastomaLiping Song
Division of Hematology Oncology, Department of Pediatrics, Childrens Hospital Los Angeles CHLA, Los Angeles, California 90027, USA
J Clin Invest 117:2702-12. 2007.... - Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology GroupJulie R Park
Department of Pediatrics, Children s Hospital and Regional Medical Center, University of Washington, Seattle, Washington 98105, USA
Pediatr Blood Cancer 52:44-50. 2009..The components of therapy required for patients with INSS Stage 3 neuroblastoma and high-risk features remain controversial... - Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trialEric Cheung
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90089, USA
Clin Genitourin Cancer 7:43-50. 2009..Fenretinide is a synthetic retinoid that is cytotoxic to a variety of cancers. We conducted a phase II trial of oral fenretinide in patients with biochemically recurrent prostate cancer... - Metabolism of orthotopic mouse brain tumor modelsMichael Rosol
Department of Radiology, Division of Hematology Oncology, Saban Research Institute at Children s Hospital Los Angeles, USA
Mol Imaging 8:199-208. 2009..The causes of these dissimilarities warrant further investigation... - E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinaseHyung Gyoo Kang
Department of Pathology and Laboratory Medicine, USC CHLA Institute for Pediatric Clinical Research, Los Angeles, California, USA
Cancer Res 67:3094-105. 2007.... - Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophiLeonid S Metelitsa
Department of Pediatrics, Division of Hematology-Oncology, Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles 90027, USA
Blood 99:4166-73. 2002..Thus, hu14.18/GM-CSF facilitates PMN ADCC against neuroblastoma cells associated with FcgammaRII and Mac-1-dependent enhanced adhesion and degranulation... - Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cellsHyung Gyoo Kang
Department of Pathology and Laboratory Medicine, Children s Hospital Los Angeles, Los Angeles, California, USA
Mol Cancer Ther 9:1396-407. 2010..EGCG may be a useful agent for targeting IGFIR, either alone or in combination, with other potentially more toxic IGFIR inhibitors for the management of EFTs...
Research Grants
- Xenograft models of human neuroblastoma bone metastases.Charles Reynolds; Fiscal Year: 2004..We anticipate that this project will increase our understanding of the biology of bone metastases and will develop mouse models for pre-clinical testing of new therapeutic approaches to high risk neuroblastoma. ..